These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21558619)

  • 1. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
    Tran L; Vogel WV; Sinaasappel M; Muller S; Baars JW; van Rijswijk M; Dinant HJ; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):7-14. PubMed ID: 21558619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
    Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
    Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
    Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
    Shaw T; Quan J; Totoritis MC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell: a logical target for treatment of rheumatoid arthritis.
    Youinou P; Jamin C; Saraux A
    Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-CD20 antibody therapy for inflammatory immune diseases].
    Tanaka Y
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rituximab treatment of rheumatoid arthritis: new evidence].
    Nasonov EL
    Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
    Bruijnen S; Tsang-A-Sjoe M; Raterman H; Ramwadhdoebe T; Vugts D; van Dongen G; Huisman M; Hoekstra O; Tak PP; Voskuyl A; van der Laken C
    Arthritis Res Ther; 2016 Nov; 18(1):266. PubMed ID: 27863504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
    Dass S; Vital EM; Emery P
    Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab: a new therapeutic alternative in rheumatoid arthritis.
    Sibilia J; Gottenberg JE; Mariette X
    Joint Bone Spine; 2008 Oct; 75(5):526-32. PubMed ID: 18571968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 14. [THE MECHANISMS OF ACTION OF RITUXIMAB].
    Gil'deeva GN; Kudlai DA; Luk'yanov SV
    Eksp Klin Farmakol; 2015; 78(12):51-6. PubMed ID: 27051930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-CD20 therapy in rheumatoid arthritis].
    Roll P; Tony HP
    Z Rheumatol; 2009 Jul; 68(5):370-9. PubMed ID: 19449019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Targeting CD20 in rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-CD20 antibody rituximab reduces the Th17 cell response.
    van de Veerdonk FL; Lauwerys B; Marijnissen RJ; Timmermans K; Di Padova F; Koenders MI; Gutierrez-Roelens I; Durez P; Netea MG; van der Meer JW; van den Berg WB; Joosten LA
    Arthritis Rheum; 2011 Jun; 63(6):1507-16. PubMed ID: 21400475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.
    Lioger B; Edupuganti SR; Mulleman D; Passot C; Desvignes C; Bejan-Angoulvant T; Thibault G; Gouilleux-Gruart V; Mélet J; Paintaud G; Ternant D
    Br J Clin Pharmacol; 2017 Aug; 83(8):1773-1781. PubMed ID: 28230269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis.
    Jung JY; Kim JW; Kim HA; Suh CH
    Expert Opin Biol Ther; 2019 Oct; 19(10):979-986. PubMed ID: 31498682
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab for rheumatoid arthritis.
    Okamoto H; Kamatani N
    N Engl J Med; 2004 Oct; 351(18):1909; author reply 1909. PubMed ID: 15509828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.